Friday, December 4, 2015


Enlibrium Finds $15M For Cancer Drugs
San Diego-based Enlibrium announced Thursday that it has raised $15M in a Series A financing, to go towards cancer therapeutics. The funding was led by Avalon Ventures and TPG Biotech, and also included Correlation Ventures and Osage University Partners. The startup said it is developing novel drugs based on the anti-cancer activity of metformin and designed to reduce cancer energy production to treat a range of cancer types. The company was founded by Dr. Michael Jung and Dr. Richard Pietras, (More info...)
posted on Friday, December 4, 2015(Full story)

ViaSat, UCSD Team On Live Sports Streaming
Carlsbad-based satellite broadband provider ViaSat and the University of California, San Diego (UCSD) said this morning they are in a new partnership, which will stream high quality sport via ViaSat's Exede satellite network. The two said they will be live streaming events at UCSDTritons.TV, powered by ViaSat's network. The two did not details any of the finances behind the deal. ViaSat said that its equipment will be operated by UCSD staff and students, with support provided by ViaSat. The firs (More info...)
posted on Friday, December 4, 2015(Full story)

EDF Renewable Energy To Build Wind Farm For Google
San Diego-based EDF Renewable Energy, which develops renewable energy projects, has released more details on the company's new renewable energy deal with Google. The company said it is building a new wind farm for Google, part of a big push by Google to move towards using renewable energy for 100 percent of Google's operations. EDF Renewable Energy said that Google has signed a Power Purchase Agreement (PPA) for 201 megawatts of wind power, which will come from the Great Western Wind Project, lo (More info...)
posted on Friday, December 4, 2015(Full story)

Amgen, Merck Team On Cancer Immmunotherapy Studies
Thousand Oaks-based Amgen and fellow biopharmaceuticals giant Merck said today that they are in a cancer immunotherapy collaboration, to support a Phase 1b/3 study. The two said the study includes both Amgen's BLINCYTO (blinatumomab) product and Merck's EKYTRUDA (pemblizumab) therapy, for treating non-Hodgkin lymphoma. The two also said they will collaborate on a Phase 1/2 study of Amgen's AMG 820 antibody to treat advanced solid tumors, including non-small cell lung, colorectal and pancreatic (More info...)
posted on Friday, December 4, 2015(Full story)